During the last session, Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s traded shares were 7.03 million, with the beta value of the company hitting 0.81. At the end of the trading day, the stock’s price was $10.98, reflecting an intraday gain of 4.17% or $0.44. The 52-week high for the RXRX share is $16.75, that puts it down -52.55 from that peak though still a striking 58.65% gain since the share price plummeted to a 52-week low of $4.54. The company’s market capitalization is $2.37B, and the average intraday trading volume over the past 10 days was 6.46 million shares, and the average trade volume was 6.86 million shares over the past three months.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
Recursion Pharmaceuticals Inc (RXRX) registered a 4.17% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 4.17% in intraday trading to $10.98, hitting a weekly high. The stock’s 5-day price performance is -3.00%, and it has moved by 0.37% in 30 days. Based on these gigs, the overall price performance for the year is 43.16%. The short interest in Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is 42.82 million shares and it means that shorts have 5.5 day(s) to cover.
Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts
Statistics show that Recursion Pharmaceuticals Inc has underperformed its competitors in share price, compared to the industry in which it operates. Recursion Pharmaceuticals Inc (RXRX) shares have gone up 28.42% during the last six months, with a year-to-date growth rate less than the industry average at -5.70% against 11.30. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -26.50% this quarter and then drop -13.20% in the quarter after that. In the rating firms’ projections, revenue will increase 28.50% compared to the previous financial year.
Revenue for the current quarter is expected to be $13.07 million as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to $13.58 million by the end of Jun 2024. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $12.13 million and $11.02 million respectively. In this case, analysts expect current quarter sales to grow by 7.70% and then jump by 23.30% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -43.41%. While earnings are projected to return -9.72% in 2024, the next five years will return 12.00% per annum.
RXRX Dividends
Recursion Pharmaceuticals Inc is due to release its next quarterly earnings between May 06 and May 10. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s Major holders
Recursion Pharmaceuticals Inc insiders own 5.77% of total outstanding shares while institutional holders control 92.37%, with the float percentage being 98.03%. Baillie Gifford and Company is the largest shareholder of the company, while 282 institutions own stock in it. As of Jun 29, 2023, the company held over 25.1 million shares (or 12.30% of all shares), a total value of $187.48 million in shares.
The next largest institutional holding, with 11.62 million shares, is of Blackrock Inc.’s that is approximately 5.69% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $86.8 million.
Also, the Mutual Funds coming in first place with the largest holdings of Recursion Pharmaceuticals Inc (RXRX) shares are ARK ETF Tr-ARK Genomic Revolution ETF and Vanguard U.S. Growth Fund. Data provided on Sep 29, 2023 indicates that ARK ETF Tr-ARK Genomic Revolution ETF owns about 6.8 million shares. This amounts to just over 3.33 percent of the company’s overall shares, with a $52.0 million market value. The same data shows that the other fund manager holds slightly less at 3.97 million, or about 1.95% of the stock, which is worth about $34.85 million.
